ReviewReviews in endocrine & metabolic disorders2016
Relapse prediction in Graves´ disease: Towards mathematical modeling of clinical, immune and genetic markers.
Review in Reviews in endocrine & metabolic disorders, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Genetic polymorphisms and early responses predict refractory hyperthyroidism during antithyroid drug therapy.iScience · 2026Article
- A Predictive Model for Graves' Disease Recurrence After Antithyroid Drug Therapy: A Retrospective Multicenter Cohort Study.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2025Observational
- A beneficial levels of 25-hydroxyvitamin D for a decrease in thyrotropin receptor antibody (TRAB) in patients with Graves' disease: a real-world study.BMC endocrine disorders · 2025Article
- Integrating shear wave elastography into clinical prediction of Graves' disease recurrence: a novel risk scoring system.Frontiers in endocrinology · 2025Article
- Enhanced predictive validity of integrative models for refractory hyperthyroidism considering baseline and early therapy characteristics: a prospective cohort study.Journal of translational medicine · 2024Article
- Clinically practical pharmacometrics computer model to evaluate and personalize pharmacotherapy in pediatric rare diseases: application to Graves' disease.Frontiers in medicine · 2023Article
- Mathematical Modeling of Free Thyroxine Concentrations During Methimazole Treatment for Graves' Disease: Development and Validation of a Computer-Aided Thyroid Treatment Method.Frontiers in endocrinology · 2022Article
- [T-lymphocytes phenotypic composition of peripheral blood in patients with Graves' disease undergoing conservative therapy with thiamazole].Problemy endokrinologii · 2021Article
- Mathematical models applied to thyroid cancer.Biophysical reviews · 2019Review
- Article
- A patient-specific treatment model for Graves' hyperthyroidism.Theoretical biology & medical modelling · 2018Article
- Elevated Serum IL-17 Expression at Cessation Associated with Graves' Disease Relapse.International journal of endocrinology · 2018Article
- Thyroid Allostasis-Adaptive Responses of Thyrotropic Feedback Control to Conditions of Strain, Stress, and Developmental Programming.Frontiers in endocrinology · 2017Review
- A journey from brain to muscle across the thyroid continent.Reviews in endocrine & metabolic disorders · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
problemGraves' disease (GD) is an important and prevalent thyroid autoimmune disorder. Standard therapy for GD consists of antithyroid drugs (ATD) with treatment periods of around 12 months but relapse is frequent. Since predictors for relapse are difficult to identify the individual decision making for optimal treatment is often arbitrary.
methodsAfter reviewing the literature on this topic we summarize important factors involved in GD and with respect to their potential for relapse prediction from markers before and after treatment. This information was used to design a mathematical model integrating thyroid hormone parameters, thyroid size, antibody titers and a complex algorithm encompassing genetic predisposition, environmental exposures and current immune activity in order to arrive at a prognostic index for relapse risk after treatment.
conclusionIn the search for a tool to analyze and predict relapse in GD mathematical modeling is a promising approach. In analogy to mathematical modeling approaches in other diseases such as viral infections, we developed a differential equation model on the basis of published clinical trials in patients with GD. Although our model needs further evaluation to be applicable in a clinical context, it provides a perspective for an important contribution to a final statistical prediction model.
Indexed as
Identifiers
27638651What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.